The impact of neoadjuvant systemic treatment on postoperative complications in breast cancer surgery

Abstract

Purpose The aim of the study was to analyze the impact of neoadjuvant systemic treatment (NST) on postoperative complications and the beginning of adjuvant treatment. Methods This study includes data from a prospectively maintained database including patients with breast cancer (BC) stage I–IV with or without NST undergoing breast cancer surgery between January 2010 and September 2021. Results Out of 517 enrolled patients, 77 received NST, 440 had primary breast surgery. After NST patients underwent surgery after a meantime of 34 days (26.5–40 days). No statistical significance could be found comparing the complication grading according to the Clavien Dindo classification. The complications were most frequently rated as grade 3b. There were no complications with grade 4 or higher. When differentiating into short and long-term, the overall rate of short-term complications was 20.3% with no significant difference between the two groups (20.8% vs. 20.2%). Regarding long-term complications, there was more impairment of shoulder mobility (26.0% vs. 9.5%, p ≤ 0.001) and chronic pain (42.9% vs. 28.6%, p ≤ 0.016) for patients with NST. The beginning of the administration of the adjuvant treatment was comparable in both groups (46.3 days vs. 50.5 days). Conclusion In our cohort, complications between both groups were comparable according to Clavien Dindo. This study shows that NST has no negative impact on postoperative short-term complications and most importantly did not lead to a delay of the beginning of adjuvant treatment. Therefore, NST can be safely admitted, even when followed by extensive breast reconstruction surgery.

Repeated Breast-Conserving Surgeries as Reflection of the Evolution in Breast Cancer Treatment (Case Report With Literature Review)

“…Better understanding of BC pathogenesis opened the possibilities to use neoadjuvant systemic treatment (NAST). NAST is used for downstaging operable BC, especially of triple-negative (TNBC) and HER2-positive, to reduce the extent of surgery and offer to patient the possibility of breast-conserving options in case of pathological complete response (pCR) [8][9][10]. However, therapeutic methods cannot yet achieve complete success in BC treatment, and surgery remains, but it no longer occupies a leading position, as before.…”